Postoperative management
PreclinicalSmall molecule
Postoperative management is one of 65 small molecule programs targeting Total Knee Arthroplasty. It is currently in Preclinical.
2
Indications
9
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
67 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Naropin
FFresenius Kabi USA, LLC
Approved
Cyklokapron
JJ Molner
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Medrol
PfizerApproved
Journavx
Vertex PharmaceuticalsApproved
Lexapro
AbbVieApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Duragesic
CCephalon
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Arthroscopic Shoulder Surgery1 trial
Total Knee Arthroplasty1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Postoperative management. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedipol University